News

Première implantation de Kalios, l’anneau mitral ajustable inventé au CHUV par l’équipe du Prof. Tozzi

February 13, 2018

Kephalios, la société française de medtech, a annoncé la première implantation chez l’homme de Kalios, son nouveau dispositif développé afin d’améliorer les résultats de la réparation chirurgicale de la valve mitrale.

L’anneau mitral ajustable a été initialement conçu et développé au CHUV avec des études pré-cliniques par l’équipe du Professeur Tozzi et son développement s’est ensuite poursuivi en France grâce au soutien de la société Kephalios. Ce dispositif permet la correction d’une insuffisance mitrale résiduelle ou récidivante, après chirurgie, sans devoir réopérer le patient. Ce procédé est considéré comme une avancée majeure dans le traitement non-invasif de l’insuffisance mitrale.

Les droits d’exploitation de cette invention sont gérés par le PACTT, l’office de transfert de technologie commun à l’UNIL et au CHUV.

Pour lire la dépêche de APM news, cliquez ici.

Applications for two venture leaders programs are open

January 25, 2018

Venture leaders Life Science 2018 in Boston

The program is an intense one-week roadshow to meet US experts and investors with a team of great Swiss based entrepreneurs, from May 27th to June 3rd, 2018.

Venture leaders China 2018 (Shanghai, Beijing, Shenzhen and Hong Kong)

For Swiss startups, China is a key market to explore. You want to discover the business potential of your innovative product/service in this huge market? Venture leaders China will help you pitch your business to investors, experts and understand the “Chinese way” of doing business. Including participation at the World Economic Forum (WEF)

SWISS COMPANY MAKER’s workshop

January 23, 2018

The SwissCompanyMaker consortium’s next workshop will be held on April 17, 18 and 25, 2018 in Bern.

This workshop invites aspiring entrepreneurs with very early to early high-technology entrepreneurial ideas in science and technology and prepares them for the entry into the existing Swiss start-up promotion ecosystem.

More info: www.swisscompanymaker.ch

Deadline for application: February 11, 2018

Application form: here

Limited number of teams participating: 12

Contact: info@swisscompanymaker.ch

Application and participation to the workshop is free of charge.

Second call for proposals for the funding scheme BRIDGE Discovery

January 18, 2018

Apply for the second call for proposals for the funding scheme BRIDGE Discovery launched by the Commission for Technology and Innovation (CTI) and the SNSF.

For more information, please click here.

New InnoTREK grant awarded to Daniel Blessing

December 15, 2017

In response to the 2017 autumn call InnoTREK Mr. Daniel Blessing (right) submitted an innovative project on the development of cardiac-specific vectors. Hosted in the experimental cardiology department at the University Hospital of Lausanne of Professor Thierry Pedrazzini (left), the financial support of the InnoTREK grant allows the laureate to mature this technology towards a start-up project over the coming year. The vectors to be developed are intended to reinforce a therapeutic approach developed by Thierry Pedrazzini (left) and Samir Ounzain (center) to treat cardiac diseases with long non-coding RNAs.

Together they will drive forward their project “HaYa Therapeutics”, an innovative technology that consists in the development and testing of a first-in-class biopharmaceutical therapy to treat heart failure and that was recently distinguished as one of the Gold Winners of the MassChallenge 2017 Switzerland.

The InnoTREK grant, organized by the PACTT with the support of the FIT as part of the InnoPACTT fund, supports selected researchers of UNIL and CHUV who have the ambition to venture into the business world with their innovative projects. These successful projects are chosen in a competitive process from applications received during the two calls per year. Since the launch in 2013, 13 laureates of UNIL and CHUV have benefited from the InnoTREK grant.

Useful links :

InnoTREK
InnoPACTT
FIT
MassChallenge

PACTT congratulates CHUV MassChallenge laureates HaYa and Lymphatica

December 1, 2017

We are proud to announce that HaYa and Lymphatica, two start-up projects from the University Hospital of Lausanne (CHUV), are amongst the gold winners of the MassChallenge Switzerland.

HaYa Therapeutics is developing a first-in-class biopharmaceutical therapy to treat heart failure. The project is the result of a strong and dynamic collaboration between Thierry Pedrazzini (right), Samir Ounzain (center) and Daniel Blessing (left).

Lymphatica Medtech SA, founded by Marco Pisano (right) and Valentina Triacca (center), is developing a micropump-based medical device for treatment of lymphedema, a chronic, disabling side effect of anti-cancer therapies. Marco Pisano was supported by the spring 2016 InnoTREK grant.

PACTT wishes full success to both teams!

Useful links :

Masschallenge website

Le Temps press release

Lymphatica website

A first patient with primary liver cancer has been treated with a technology invented at the CHUV and licensed to Biocompatibles by the PACTT

November 16, 2017

In August 2015, PACTT was pleased to announce the signature of a license agreement and a development collaboration between CHUV and Biocompatibles International plc, part of the specialist healthcare company BTG plc, for a technology developed by Professor Alban Denys at the Radiodiagnostic and Interventional Radiology Unit at the CHUV. The technology enables the treatment of liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver

The UCL Cancer Institute and BTG plc have now begun to enroll patients into the first clinical trial. For Professor Denys “it is a great satisfaction to see this technology now entering the clinical stage, providing patients with liver cancer hope for additional treatment options.”

Tor read the complete presse relase, please click here.

For BTG website, please click here.